Iressa shows promise for treatment of metastatic breast cancer w...

Courtesy EurekAlert! - Medicine and Health  Thu, 05/15/2008 - 23:00

(University of Texas M. D. Anderson Cancer Center) Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M.

D. Anderson Cancer Center.

Tags:

 

Related news items

Faulty DNA repair could be a risk factor for lung cancer in nons...
(American Association for Cancer Research) People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at...

Metformin increases pathologic complete response rates in breast...
(University of Texas M. D. Anderson Cancer Center) Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing...

Gene therapy increases survival for end-stage head and neck canc...
(University of Texas M. D. Anderson Cancer Center) A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to...

Stabilizing cancer-fighting p53 can also shield a metastasis-pro...
(University of Texas M. D. Anderson Cancer Center) Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the...

M. D. Anderson nurse addresses lymphedema in breast cancer patie...
(University of Texas M. D. Anderson Cancer Center) A poster session presented today by the University of Texas M. D. Anderson Cancer Center at the...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com